Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Aftaid; Aphthasol; Aptheal; Apthera; CHX 3673; Miraftil; OraDisc A; OraRinse™

Latest Information Update: 13 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Pharmascience; ULURU
  • Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiulcers; Small molecules
  • Mechanism of Action Histamine release inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Aphthous stomatitis

Highest Development Phases

  • Market Withdrawal Aphthous stomatitis
  • Discontinued Atopic dermatitis; Mouth disorders; Mucositis

Most Recent Events

  • 05 Jul 2017 Amlexanox topical patch (OraDisc™ A) is available for licensing in USA as of 05 Jul 2017. https://www.uluruinc.info/
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top